Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:00 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
NCT05636176 · Novo Nordisk A/S · PHASE3 · terminated · last registry update 2026-10-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No longer looking for participants.” | – | Registry record, Novo Nordisk A/S |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL6 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-02Phase 3 first posted: Merck Sharp & Dohme LLC, Gocatamig + Durvalumab (NCT07908537)
- 2026-10-30Results posted on the registry: Stanley Jordan, MD, Clazakizumab (NCT03380962)
- 2026-08-11Results posted on the registry: Tourmaline Bio, Inc., a Novartis Company, TOUR006 - 50 MG + TOUR006 - 25 MG (NCT06362759)
- 2026-06-26Phase 3 first posted: R-Pharm International, LLC, Olokizumab + Placebo (NCT07670546)
- 2026-06-04Phase 3 first posted: R-Pharm International, LLC, Placebo + Goflikicept (NCT07625384)
- 2026-06-03Results posted on the registry: University of Alabama at Birmingham, Siltuximab (NCT04975555)
- 2026-05-06Phase 3 first posted: Merck Sharp & Dohme LLC, MK-1045 + Blinatumomab (NCT07570173)
- 2026-05-06Results posted on the registry: Novo Nordisk A/S, Ziltivekimab + Placebo (ziltivekimab) (NCT04626505)
- 2026-04-01Results posted on the registry: University of North Carolina, Chapel Hill, MCT + Clazakizumab (NCT04129931)
- 2026-02-05Also stopped (terminated): H. Lee Moffitt Cancer Center and Research Institute, Siltuximab (NCT05316116)
- 2025-12-24Phase 3 first posted: Novo Nordisk A/S, Ziltivekimab + Ziltivekimab Placebo (NCT07301034)
- 2025-12-11Phase 3 first posted: ECRI bv, Ziltivekimab + Placebo (NCT07276282)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision